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Intensive care in patients with lung cancer: a multinational study Background: Detailed information about lung cancer patients requiring admission to intensive care units (ICUs) is mostly restricted to single-center studies. Our aim was to evaluate the clinical characteristics and outcomes of lung cancer patients admitted to ICUs.
Patients and methods: Prospective multicenter study in 449 patients with lung cancer (small cell, n = 55; non-small cell, n = 394) admitted to 22 ICUs in six countries in Europe and South America during 2011. Multivariate Cox proportional hazards frailty models were built to identify characteristics associated with 30-day and 6-month mortality.
Results: Most of the patients (71%) had newly diagnosed cancer. Cancer-related complications occurred in 56% of patients; the most common was tumoral airway involvement (26%). Ventilatory support was required in 53% of patients. Overall hospital, 30-day, and 6-month mortality rates were 39%, 41%, and 55%, respectively. After adjustment for type of admission and early treatment-limitation decisions, determinants of mortality were organ dysfunction severity, poor performance status (PS), recurrent/progressive cancer, and cancer-related complications. Mortality rates were far lower in the patient subset with nonrecurrent/progressive cancer and a good PS, even those with sepsis, multiple organ dysfunctions, and need for ventilatory support. Mortality was also lower in high-volume centers. Poor PS predicted failure to receive the initially planned cancer treatment after hospital discharge. Lung cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related mortality worldwide [1] . Despite advances in the management, overall long-term survival remains poor particularly in patients with non-resectable or metastatic tumors [2] . Nevertheless, complete recovery or prolonged survival can be achieved in some patients with non-small-cell lung cancer (NSCLC) [3] [4] [5] .
Lung cancer patients account for ∼8% of all intensive care unit (ICU) admissions of patients with malignancies and 27% of those with solid cancer [6, 7] . Over the last decade, improvement in these patients was reported worldwide [8] [9] [10] [11] [12] [13] . However, lung cancer patients are usually perceived as having substantially worse ICU outcomes compared with other cancer patients. Therefore, ICU admission for life-threatening events is still widely viewed as unlikely to benefit these patients, particularly when ventilatory support is needed [14, 15] .
The available information about lung cancer patients requiring ICU admission comes chiefly from single-center studies reporting ICU or hospital mortality rates in small groups of patients [8] [9] [10] [11] [12] [13] [14] [15] . Recently, however, two studies used administrative databases to evaluate the outcomes of lung cancer patients admitted to the ICU [16, 17] . Nevertheless, both were conducted in a single country (the United States), and did not provide detailed information about the reasons for ICU admission, characteristics of the lung malignancies, or anticancer treatments. Moreover, data on the clinical course and anticancer treatment continuation rates in ICU survivors are very limited [10] .
Here, our objective was to study a large population of critically ill patients with lung cancer admitted to European or South American ICUs, in order to describe their clinical characteristics and outcomes and to identify factors associated with short-and long-term mortality.
patients and methods

design and setting
This prospective multinational cohort study was conducted in 22 ICUs in Argentina (n = 1), Brazil (n = 5), Chile (n = 1), France (n = 10), the UK (n = 2), and Uruguay (n = 3) throughout 2011. All participating investigators and centers are listed in the Appendix of the supplementary Material, available at Annals of Oncology online. The study was observational, with all clinical decisions left to the attending physicians. The study was approved initially by the Brazilian National Ethics Committee (approval number CONEP 15.790) and subsequently by local and national ethics committees in the participating centers and countries. In the few centers that required informed consent for the study, written informed consent was obtained from each patient or legal representative before study inclusion. patient selection, data collection, and definitions Consecutive patients aged ≥18 years with a diagnosis of lung cancer requiring ICU admission at the participating centers were evaluated. We did not include patients with ICU stays <24 h, complete cancer remission for >5 years, previous ICU admission, malignancies other than primary lung cancer, or unwillingness to participate in the study.
Demographic, clinical, and laboratory data collected included hospital location before ICU, reason for ICU admission, Eastern Cooperative Oncology Group performance status (ECOG-PS) during the week before ICU admission [18] , Simplified Acute Physiology Score II [19] , Sequential Organ Failure Assessment (SOFA) score [20] , and comorbidities with determination of the Charlson Comorbidity Index [21] . The use during the ICU stay of ventilatory support (invasive and noninvasive mechanical ventilation) for >24 h, vasopressors, and renal replacement therapy were recorded. Cancerrelated data included histological type, cancer stage [22] , anticancer treatments (radiation, chemotherapy, and surgical resection), cancer-related complications, and cancer status (newly diagnosed, recurrent/progressive, or in remission). Lung cancer was considered a reason for ventilatory support in patients with bilateral lung involvement, carcinomatous lymphangitis, or tumor masses causing airway obstruction [8] . All patients were followed up until hospital discharge. In addition, hospital survivors were followed up until 6 months after ICU admission and information was assessed during clinical consultations or phone calls.
data entry and processing
Data were collected using a web-based standardized electronic case report form developed specifically for the study. All investigators and research coordinators had access to the website, which contained all the study documents including a manual detailing the data collection requirements and definitions. The investigators could contact the steering committee members and country coordinators by telephone and email if needed. Local investigators completed a form reporting the ICU and hospital characteristics and were responsible for supervising data collection and checking data completeness and quality. Data were screened by a single investigator (MS) for missing information, implausible and outlying values, and lack of detail; this investigator contacted the local investigators as needed to resolve these issues.
statistical analysis
Continuous variables were reported as mean ± SD or median (25%-75% interquartile range, IQR). Patients were managed in different centers, giving the data a multilevel structure. We used a shared frailty model to identify factors associated with death (PROC PHREG SAS 9.3). Risk factors for 30-day and 6-month mortality were estimated using a Cox proportional hazards frailty model. The center effect was handled as a random effect in the model. Variables included in the multivariate model were those yielding P values <0.25 in univariate frailty models. Center-and patient-related variables yielding P values <0.05 in the multivariate context were kept in the model. Survival curves were plotted using the Kaplan-Meier method. All statistical analyses were carried out using SAS 9.3 (SAS Institute, Cary, NC). P values <0.05 were considered significant. Figure S1 , available at Annals of Oncology online.
patient characteristics. Tables 1 and 2 report the main characteristics of the 449 patients included in the study. The main reasons for ICU admission were postoperative complications (41%), acute respiratory failure (23%), and sepsis (21%). There were 394 (88%) patients with NSCLC and 55 (12%) patients with small-cell lung cancer (SCLC). Median time since cancer diagnosis was 74 (IQR, 22-185) days. Anticancer treatments before the present hospital admission included surgical resection (17%), radiation therapy (22%), and singledrug or combination chemotherapy (42%). More than half the patients had cancer-related complications at ICU admission, with the most common being airway compromise by the tumor (Table 2) .
outcome analysis
Considering all 449 patients, the in-ICU, in-hospital, 30-day, and 6-month mortality rates were 28%, 39%, 41%, and 55%, Table 3 reports the results of the multivariate analyses. After adjustment for type of admission and TLD taken on the first ICU day, the main determinants of 30-day and 6-month mortality were higher SOFA scores, poor PS, recurrent/progressive cancer, and presence of cancer-related complications (airway compromise, deep vein thrombosis, or superior vena cava syndrome). Lower mortality was seen at 30 days and at 6 months in high-volume centers. Histological type of cancer was not associated with mortality. Figure 1 shows mortality rates according to the main combinations of PS, cancer status, and treatment requirements. Survival curves for all patients and subsets defined based on prognostic factors are provided in supplementary Figure S2A -F, available at Annals of Oncology online). emergency anticancer treatments during the ICU stay Twenty-five (NSCLC = 14; SCLC = 11) patients received emergency anticancer treatments (chemotherapy, n = 20; radiation therapy, n = 4; both, n = 1) in the ICU. In 17 of 25 (68%) patients, the reason for emergency anticancer treatment was cancer-related severe acute complications being the most frequent airway compromise (56%) and large pleural/pericardial effusion (44%). No severe treatment-related complications occurred during the ICU stay. In-ICU, in-hospital, and 6-month mortality rates in these 25 patients were 36%, 44%, and 68%, respectively.
picture of hospital survivors
Of the 449 patients, 275 (NSCLC = 246; SCLC = 29) were discharged alive from the hospital. Among them, 200 (73%) were known to be alive at 6 months and 72 (26%) had died; vital status was unknown for 3 (1%) patients. Cancer recurrence or progression occurred in 53 (26%) hospital survivors and, as expected, was more frequent in patients with stage III/IV (39% and 48%, respectively) NSCLC or extensive SCLC (57%). Anticancer treatments were recommended to 108 (39%) hospital survivors and administered to 102; anticancer treatment was not recommended to 121 (44%) patients and information on this item was not available for 46 (17%) patients. In the 102 treated patients, the treatments used were variable combinations of surgical resection (7%), radiation therapy (34%), and chemotherapy (80%). In 35 (34%) patients, the initial anticancer treatment plan required reduction or modification. Posthospital mortality was nonsignificantly lower in the patients given the initial treatment plan than in the other patients (17% versus 32%, P = 0.065). Poor PS was the only factor associated with a lower probability of receiving the initial treatment plan (odds ratio, 0.20; 95% confidence interval 0.05-0.87; P = 0.032). Among the 200 patients alive at 6 months, 142 (71%) were at home, 30 (15%) were hospitalized, and 14 (7%) were in hospice care; the location was unknown for 12 (6%) patients. PS at 6 months was 3-4 in 19 (9.5%) survivors.
discussion
This multinational study obtained prospective data in a large population of lung cancer patients admitted to the ICU. Lung cancer patients accounted for 3.5% of all ICU admissions. Their Table 3 . Cox proportional hazards frailty models of characteristics associated with 30-day and 6-month mortality (n = 449) a Survival 6 months after ICU admission. Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. b There was a significant interaction between SOFA scores and type of admission in the model with censoring at 6 months (P = 0.009).
c There was a significant interaction between cancer status and treatment-limitation decision on ICU day 1 in both models (P = 0.002). mortality rates were comparable with those in unselected cancer patients requiring ICU admission in previous multicenter studies [6, 7] . Slightly over one-third of hospital survivors received anticancer treatments after discharge. Most of 6-month survivors were living at home. In recent years, several specialized centers reported improved outcomes after ICU admission of lung cancer patients [8] [9] [10] [11] [12] [13] . Two studies were published recently using administrative databases in the United States did not provide information on many relevant clinical characteristics [16, 17] . One study used the Surveillance, Epidemiology, and End Results (SEER) Medicare registry in the United States to identify 49 373 patients with lung cancer admitted to the ICU for reasons other than surgical resection over a 14-year period [17] . Only 21% of patients received mechanical ventilation (compared with 53% in our study) and the hospital mortality was 24% (compared with 39%). Thus, the patients in this study seem to have had less severe disease than those in our population, perhaps as a result of stricter triage policies. In contrast to earlier studies, we considered both center-and patient-related variables in our assessment of factors potentially associated with mortality. After adjustment for medical versus surgical ICU admission and early TLD, in addition to the severity of acute organ dysfunctions, three main factors were associated with increased 6-month mortality: poor PS before ICU admission, recurrent or progressive cancer, and presence of serious cancer-related complications. PS before ICU admission was closely associated with 30-day and 6-month mortality across the range of clinical presentations. In addition, a poor PS also predicted inability to receive the initial anticancer treatment plan in hospital survivors. Importantly, admission to high-volume centers was associated with lower mortality. This effect may be related to expertise, closer collaboration between oncologists and intensivists, or more efficient ICU triage policies.
At ICU admission, about half the patients had cancer-related complications, some of which required emergency treatment. Thus, 25 patients received emergent chemotherapy and/or radiation therapy in the ICU. These treatments were not associated with increased mortality or acute toxicities, although their impact on the long-term-outcome is unclear. Hospital and 6-month mortality rates of 44% and 68%, respectively, in these 25 patients suggest that rescue anticancer treatment started in the ICU may be of benefit in highly selected patients.
Strengths of our study include the large number of patients from different countries admitted not only in referral cancer centers, but also in general hospitals. Patient recruitment over a single year minimized the possible influence of changes in treatment modalities over time. A limitation of our study is that we included patients admitted to a convenience sample of centers in six countries. Therefore, our population cannot be considered representative of all lung cancer patients admitted to the ICU. In addition, we obtained data only for the first 6 months after ICU admission. Information on longer term outcomes is needed. Finally, we did not collect data on quality of life.
In conclusion, in this multinational study, ICU admission provided substantial survival rates in patients with good PS and non-recurrent/progressive disease, including those who had severe acute complications such as sepsis, multiple organ failure, and need for ventilatory support. In addition, more than a third of the hospital survivors received anticancer treatment. PS before ICU admission was associated with both mortality and ability to receive optimal anticancer treatment after hospital 
